.jpg)
Vitality Unleashed: The Functional Medicine Podcast
Welcome to Vitality Unleashed: The Functional Medicine Podcast, your ultimate guide to achieving holistic health and wellness. Created and vetted, by Dr. Kumar from LifeWell MD a dedicated functional medicine physician, this podcast dives deep into the interconnected realms of physical, emotional, and sexual health. Carefully curated medical insights to expand your options, renew hope, and ignite healing—especially when traditional medicine has no answers.
Each week, we unpack the complexities of the human body-mind, exploring topics like hormone balance, gut health, mental resilience, difficult medical conditions, power performance and intimate relationships.
Join us as we bridge the gap between complex medical science and everyday understanding. We transform the latest research and intricate information from the world of medical academia into simple, actionable insights for everyone. Think of us as your Rosetta Stone for health—making the complicated easy to grasp. Enjoy inspiring and practical advice that empowers you to take charge of your health journey. Whether you're seeking to boost your energy, enhance your emotional well-being, or revitalize your sexual health, this podcast provides the tools and knowledge you need.
Embark on this transformative journey with us, and discover how functional medicine can help you live a vibrant, balanced, and fulfilling life. Subscribe to Vitality Unleashed today, and let's redefine what it means to be truly healthy—mind, body, and soul.
Vitality Unleashed: The Functional Medicine Podcast
Colchicine After Heart Attack: A Revolutionary Discovery
A revolutionary discovery in heart attack care emerges from the pages of the New England Journal of Medicine, where researchers have found an unexpected hero in colchicine—a medication derived from the autumn crocus plant and used for centuries to treat gout and other inflammatory conditions.
The COLCOT trial (Colchicine Cardiovascular Outcomes Trial) reveals something remarkable: this ancient, inexpensive anti-inflammatory medication reduced the risk of major cardiovascular events by 23% in patients recovering from heart attacks. Most strikingly, it slashed stroke risk by an astonishing 74% and halved the need for urgent procedures due to chest pain. These benefits appeared despite patients already receiving optimal standard care with statins, aspirin, and other treatments.
What makes this discovery particularly exciting is how it validates the inflammation hypothesis of heart disease. While we've long focused on cholesterol and blood clotting as primary targets in cardiovascular care, this research confirms inflammation isn't just a bystander but an active contributor to heart problems. By interfering with cellular microtubules and dampening inflammatory pathways, colchicine provides protection through an entirely different mechanism than our current approaches.
The implications reach far beyond academic interest. For the millions of people who suffer heart attacks each year, this readily available medication could transform recovery outcomes. Though researchers noted mild digestive side effects and a small increased pneumonia risk that warrants monitoring, the overall safety profile appeared favorable. This represents exactly the kind of innovative thinking we need to advance heart health—finding new uses for established medications with well-understood safety profiles. Could your heart health strategy benefit from addressing inflammation? Connect with us to explore how these cutting-edge findings might fit into your personal wellness journey.
Disclaimer:
The information provided in this podcast is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before making changes to your supplement regimen or health routine. Individual needs and reactions vary, so it’s important to make informed decisions with the guidance of your physician.
Connect with Us:
If you enjoyed today’s episode, be sure to subscribe, leave us a review, and share it with someone who might benefit. For more insights and updates, visit our website at Lifewellmd.com.
Stay Informed, Stay Healthy:
Remember, informed choices lead to better health. Until next time, be well and take care of yourself.
Welcome to the Deep Dive. We're here to explore medical research and really bring you key insights for a healthier life. It's your fast track to staying informed.
Speaker 2:And we're part of the team at LifeWellMDcom here in Florida focused on health, wellness and longevity. Definitely check out the website for more info.
Speaker 1:Today we are taking a deep dive into a well, a really interesting study. It just came out in the New England Journal of Medicine.
Speaker 2:Yeah, it's looking at a potential game changer for heart health and it involves a drug many folks already know. Actually, Colchicine, colchicine you know, I think most people like you said, they hear colchicine, they think gout right or maybe pericarditis, heart health probably doesn't even come up.
Speaker 1:Yeah.
Speaker 2:So okay, let's unpack this. This sounds really important.
Speaker 1:It is.
Speaker 2:Our mission today really is to understand what this research found. What could it mean for preventing future heart problems, specifically after a heart attack?
Speaker 1:Exactly, and this is the kind of, you know, potentially transformative information that we at Life LMD are always tracking. It could be crucial for your wellness journey, definitely. So. To really get this colchicine study, we probably need some background first. Inflammation and heart disease, right. What's the link there?
Speaker 2:Right. Well, it's pretty well established now. We've known for quite a while that inflammation is a key player in atherosclerosis.
Speaker 1:That's the plaque buildup in the arteries.
Speaker 2:Exactly the stuff that can lead to heart attacks and strokes. So inflammation is deeply involved in that whole process.
Speaker 1:So it's not just, you know, cholesterol, there's this whole other angle. Weren't there some previous attempts to target inflammation for heart disease? How did those go?
Speaker 2:Yeah, there's been a lot of interest there. So, for example, the CANTOS trial looked at a drug called canakinumab. It targeted a specific inflammatory protein and it did show about a 15% lower risk of cardiovascular events. But there was a catch it also led to an increased risk of serious infections, some even fatal. So, that was a major concern.
Speaker 1:Okay, not ideal.
Speaker 2:Not ideal. Then there was another study, the CR trial, which looked at methotrexate. That's a common anti-inflammatory drug.
Speaker 1:Right used for arthritis and things.
Speaker 2:Exactly, but unfortunately it showed no benefit at all for cardiovascular outcomes in that study.
Speaker 1:Huh, so the search was definitely still on for something safe and effective.
Speaker 2:Precisely, which brings us back to colchicine.
Speaker 1:Okay, so colchicine, you said people know it. It's not a new drug then.
Speaker 2:Oh, not at all, it's actually. Well, it's ancient really. It comes from the autumn crocus plant. It's been used for centuries.
Speaker 1:Centuries wow.
Speaker 2:Yeah, and it's inexpensive. You take it orally and it's a potent anti-inflammatory.
Speaker 1:So how does it work? What's it doing inside the body to fight inflammation?
Speaker 2:Well, its main mechanism is pretty interesting. It interferes with something called tubulin polymerization. Basically, it messes with the internal scaffolding, the microtubules inside cells.
Speaker 1:Okay.
Speaker 2:And by doing that it seems to dampen down various inflammatory pathways. The study mentions effects on things like cell adhesion molecules, certain signaling chemicals called cumakines and even this key immune complex called the inflammasome.
Speaker 1:The inflammasome. That sounds important.
Speaker 2:It really is a central hub for inflammation.
Speaker 1:And just quickly, what's colchicine normally used for the approved uses?
Speaker 2:Right. So typically it's for gout, as we mentioned also familial Mediterranean fever, which is a genetic inflammatory condition, and pericarditis that's inflammation around the heart.
Speaker 1:Got it Now. I feel like I heard something about colchicine and heart disease before this big study. Was there an earlier trial?
Speaker 2:You're probably thinking of the LODOCO trial, lodoco.
Speaker 1:LODOCO yeah.
Speaker 2:Yeah, that one looked at low-dose colchicine for people with stable coronary disease and it did suggest fewer cardiovascular events. But there's always a but Well, yeah, it was a smaller study and, critically, it didn't have a placebo group, it wasn't placebo-controlled.
Speaker 1:Okay, so harder to know for sure if the drug was really responsible.
Speaker 2:Exactly, which is why this new study, the COLCOT trial, is such a big deal. It was designed to give us much clearer answers.
Speaker 1:COLCOT. Ok, so tell us about the setup. How did they design this Colcott trial?
Speaker 2:So Colcott stands for Colchicine Cardiovascular Outcomes Trial, and its specific goal was to rigorously test Colchicine after a heart attack, looking at both cardiovascular outcomes and long term safety.
Speaker 1:Right.
Speaker 2:It's a randomized double blind placebo controlled trial. That's really the gold standard design.
Speaker 1:Double-blind, meaning neither the patients nor the doctors knew who was getting the actual colchicine and who got the placebo correct.
Speaker 2:Precisely Minimizes bias. Patients got a low dose, just 0.5 milligrams once a day.
Speaker 1:Okay.
Speaker 2:And the participants were adults, all within 30 days of having a heart attack. Importantly, they'd already had procedures like angioplasty or stents if needed, and they were already on standard treatments.
Speaker 1:Standard treatments like statins.
Speaker 2:Yes, including intensive statin therapy, aspirin, other anti-platelets. That works guideline recommended care. There were some exclusions, of course, like people with severe heart failure or who'd had a very recent stroke.
Speaker 1:Makes sense. And what were they primarily looking for? What was the the primary endpoint.
Speaker 2:The main thing they measured was a composite. It included several major events bundled together death from cardiovascular causes, resuscitated cardiac arrest, another heart attack, stroke or an urgent hospitalization for angina chest pain that required another procedure like stenting.
Speaker 1:Okay, quite a comprehensive list. How many people and for how long.
Speaker 2:They enrolled 40745 patients and the median follow-up time was around 22.6 months, so almost two years.
Speaker 1:Almost two years. Okay, the moment of truth. What did they find? What were the results?
Speaker 2:Well, the headline finding is that the primary outcome was significantly lower in the coltacine group.
Speaker 1:Significantly lower.
Speaker 2:Yes, it occurred in 5.5% of patients taking coltacine, compared to 7.1 percent in the placebo group. That translates to a hazard ratio of 0.77. And the p-value was 0.02, which indicates statistical significance. So a clear reduction in risk for that combined endpoint.
Speaker 1:Wow, that's pretty impressive. A 23 percent relative risk reduction roughly Right. Can you break down that primary endpoint? Did colpsin affect all those components equally, or were some drivers bigger than others?
Speaker 2:Great question and yes, there were differences. The most striking effects were seen for stroke and for urgent hospitalization for angina needing revascularization.
Speaker 1:Really Stroke.
Speaker 2:Yeah, the risk of stroke was reduced substantially. The hazard ratio is 0.26. That's a huge drop 74% relative reduction.
Speaker 1:That's amazing.
Speaker 2:It is, and for the urgent hospitalization for angina needing a procedure, the hazard ratio was 0.50. So basically a halving of that risk.
Speaker 1:Also very significant. What about the other things? Heart attack, cardiac arrest, cardiovascular death.
Speaker 2:For those components cardiovascular death, resuscitating cardiac arrest and subsequent myocardial infarction the hazard ratios actually weren't statistically significant on their own.
Speaker 1:Oh, okay.
Speaker 2:The numbers sort of trended in the right direction, favoring colchicine, but they didn't reach statistical significance individually. So it looks like the overall benefit was really driven by that reduction in stroke and the urgent revascularization for angina.
Speaker 1:I see. So the main drivers were stroke and repeat procedures for chest pain. Did they look at any other combined endpoints?
Speaker 2:They did. They had a secondary endpoint which was a composite of just death from cardiovascular causes, cardiac arrest, mi or stroke.
Speaker 1:Yeah.
Speaker 2:So similar to the primary, but without the urgent revascularization part. For that secondary endpoint the hazard ratio was 0.85, and that was not statistically significant.
Speaker 1:Okay, but the primary endpoint, which included that clinically important outcome of needing another procedure, was significant.
Speaker 2:Correct. That's the key takeaway on efficacy.
Speaker 1:And it's really worth stressing again right, this benefit was seen in patients who are already getting good standard care aspirin, statins, everything.
Speaker 2:Absolutely. That's what makes it potentially so important. It suggests colchicine is adding something on top of our current best treatments. It implies that targeting this inflammation pathway gives an extra layer of protection.
Speaker 1:Okay, crucial piece Now the flip side safety. Any medication can have side effects. What did they see with colchicine in this trial?
Speaker 2:Good question. Overall, the rate of adverse events thought to be related to the study drug was pretty similar between the colchicine and placebo groups. The most commonly reported things, and perhaps expected with colchicine, were gastrointestinal issues. There was slightly more diarrhea in the colchicine group, 9.7% versus 8.9%, though that difference wasn't statistically significant. Nausea was also a bit higher, 1.8% versus 1.0% of that was statistically significant.
Speaker 1:All right, so mostly some mild tummy upset. Potentially Anything more serious pop up.
Speaker 2:Yes, and this is important. There was a higher incidence of pneumonia reported as a serious adverse event in the colchicine group. It was 0.9% versus 0.4% in the placebo group and that difference was statistically significant. Pneumonia Okay. That's also worth pointing out that, unlike that canakinumab drug from the Kantos trial, colchicine did not increase the risk of septic shock.
Speaker 1:Right.
Speaker 2:And another reassuring point even though almost all these patients were on high-intensity statins, there was no signal of serious muscle problems or myopathy linked to the colchicine.
Speaker 1:Okay, that's good news on the muscle front, given the statin use, but the pneumonia signal is there. So, pulling it all together, what are the main implications here? The big picture from Colcott.
Speaker 2:Well, the main conclusion is pretty clear Low-dose colchicine given soon after a heart attack significantly cuts the risk of major ischemic cardiovascular events.
Speaker 1:Okay.
Speaker 2:And that benefit seems largely driven by reducing strokes and the need for urgent procedures due to angina.
Speaker 1:But we need to be a little careful about how far we extend this right. This was a specific group post-heart attack patients and the follow-up was just under two years.
Speaker 2:That's exactly right. It's a limitation. We don't know the effects beyond that, say five or ten years out. So longer term studies are definitely needed to see if the benefit holds up and if any safety issues emerge over time. And yes, these results apply specifically to people who've just had an MI. We can't just assume it works the same way for, say, someone with stable angina or other groups.
Speaker 1:Makes sense. But it really hammers home that point about inflammation, doesn't it? It suggests tackling inflammation directly. Even with an old drug like colchicine can make a real difference, on top of controlling cholesterol and platelets.
Speaker 2:Precisely. It adds significant weight to the inflammation hypothesis of cardiovascular disease. It tells us that inflammation isn't just a bystander, it's an active target for therapy.
Speaker 1:So, wrapping up here, this major study suggests that colchicine a drug most people, maybe even many doctors, only associate with gout, might actually be a valuable tool after a heart attack. It's cheap, it's available and it seems to add another layer of protection by reducing inflammation. It's quite surprising really. This kind of information could genuinely change how we approach care after a heart attack. It really underscores, you know, how much we're still learning and the importance of looking for new angles in preventing heart disease.
Speaker 2:Absolutely. It's a great example of how ongoing research, even with older medications, can lead to potentially significant advances for patients.
Speaker 1:And for you listening. If you or someone you care about has had a heart attack, or if you're just keen on staying ahead of the curve with heart health and prevention, well, this is exactly the kind of cutting-edge research we follow closely here at LifeWellMDcom in Florida. That's right, we're committed to bringing these innovative strategies in health, wellness and longevity to our community. If you want to learn more about this colchicine research or discuss how the latest science might fit into your personal wellness plan, please give our team at LifeWellMD a call. The number is 561-210-9999. Let us help you start your personalized wellness journey today.
Speaker 2:It really leaves you thinking, doesn't it? What if this simple existing medication could truly alter the long-term path for heart health in a way we're just now starting to appreciate? It opens up some very exciting possibilities to explore further.